Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields + Chemoradiation + Durvalumab in Stage III NSCLC
NCT06124118Phase 1Withdrawn
- Sponsor
- University of Utah
- Start
- Apr 2024
- Primary completion
- Nov 2026
01
Overview
Phase 1, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Utah. Primary endpoint: Rate of dose-limiting toxicities at 12 weeks. Planned start Apr 2024; status: withdrawn.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06124118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124118.